EUVIMEDEUVIMED entdecken
CrossrefInfokarte

A Mito-CoQ10-TPP Nanocarrier Hybrid Enhances the Therapeutic Efficacy of Mitochondrial Transplantation in Alzheimer’s Disease

Nitika Sindhu, Smita Jain, Swapnil Sharma, Swati Paliwal

ACS Chemical Neuroscience · 2026-10-27

DOI: 10.1021/acschemneuro.6c00379 ↗
AbstractBibliografische Angaben

Abstract

Abstract Mitochondrial dysfunction is an early pathological aspect of Alzheimer’s disease (AD) that promotes oxidative stress, leading to amyloid β-plaque formation and neurofibrillary tangles. Thus, targeted mitochondrial therapy and mitochondrial transplantation have emerged as promising therapeutic strategies. However, excessive oxidative stress and neuroinflammation in the microenvironments of the AD brain limit the functional and stable integration of transplanted mitochondria. In this study, we have engineered a Mito-CoQ10-TPP hybrid nanocarrier by conjugating triphenylphosphonium (TPP), a lipophilic cation, with Coenzyme Q10 (CoQ10) and localized it to mitochondria isolated from healthy cortical brain cells. This nanocarrier hybrid was administered via a single intravenous (IV) dose to streptozotocin (STZ)-induced AD in mice. A comprehensive evaluation of mitochondrial function, amyloid burden, neuroinflammation, apoptosis, biogenesis, and behavior revealed that CoQ10-TPP conjugation significantly improved the mitochondrial transplantation efficacy in the amelioration of AD. Thus, conjugating the antioxidant CoQ10 with mitochondrial transplantation significantly improved the overall therapeutic efficacy, indicating the use of the Mito-CoQ10-TPP hybrid nanocarrier as a promising therapeutic strategy.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →